Trending News

Cancer cells
#ASCO #Cancer therapeutics #Cancer treatment #Cancer vaccine #Oncology

Five 2024 breakthroughs in cancer drug research

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More

#Cancer Research #News #Trending News

Ozempic Insulin injection pen
#ASCO #Case Western Reserve University #Oncology #Weight loss

Ozempic reduces risk of 13 types of cancer

Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More

#Cancer Research #News #Trending News

Conference speaker
#ASCO #Clinical trials #Drug discovery #Events #Oncology #Preclinical investigations

ASCO 2024 research highlights

As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. RP1 and RP2 for melanoma… Read More

#Cancer Research #News #Trending News

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

Vaccine
#BioNTech #Cancer vaccine #Clinical trials #mRNA #Oncology #UK

NHS England launches country-wide cancer vaccine trials

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments. The vaccines being jointly developed by biopharmaceutical companies BioNTech and Genentech are… Read More

#Cancer Research #News #Trending News

Digestive Health Day
#Digestive health #Gastrointestinal #Napo Pharmaceuticals #Plant-based

Plant-based drug reduces symptoms in functional diarrhoea patients

This World Digestive Health Day, Napo Pharmaceuticals has announced positive results of a third-party, investigator-initiated study of crofelemer, Napo’s novel plant-based prescription drug. The study results show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and… Read More

#News #Trending News

#Diabetes #GlobalData #Market reporting #Weight loss

GLP-1 receptor agonists market to reach $125 billion by 2033

Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData. GLP-1 receptor agonists like Ozempic (semaglutide) are a class of incretin mimetic medicines for the treatment of… Read More

#News #Trending News #Trends & Analysis

Patient using blood pressure monitor
#Cardiovascular disease #Novo Nordisk #Obesity #University College London #Weight loss

Ozempic could be a gamechanger for cardiovascular disease

Semaglutide (the active ingredient in Wegovy and Ozempic) can produce clinically meaningful weight loss and delivers significant cardiovascular benefits, according to two studies presented at the European Congress on Obesity (ECO). The studies are based on the Semaglutide and Cardiovascular Outcomes (SELECT) trial, the largest and… Read More

#News #Trending News

Child having a hearing test
#Gene mutation #Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Rare disease

Gene therapy cures profound genetic deafness within 24 weeks

The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference. Initial hearing improvements have also been observed… Read More

#News #Trending News

Child receiving treatment for malaria
#Africa #Clinical trial #Malaria #Monoclonal antibodies #Therapeutic Antibodies

Experimental malaria monoclonal antibody prevents infection

A single injection of an experimental monoclonal antibody called L9LS was 77% effective at preventing malaria infection in children in Mali, according to the results of a mid-stage clinical trial. L9LS binds to and neutralises ‘sporozoites’, the form of the malaria parasite transmitted by mosquitoes that… Read More

#News #Trending News

Microbiome
#Microbiome #National Cancer Institute #National Institutes of Health (NIH) #Oncology #The Francis Crick Institute #vitamin D

Vitamin D boosts ‘good’ bacteria and improves immunity to cancer

Researchers have found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer. The researchers from the Francis Crick Institute, the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) and Aalborg University in… Read More

#Cancer Research #News #Trending News

#Antibodies #Artificial intelligence (AI) #Biologics #Investment #Seed funding #Start-ups

AI drug discovery company Xaira launches with $1b investment

Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More

#News #Start-up Zone #Trending News

Parkinson's disease
#AskBio #Cell and gene therapy #Gene therapy #Neurodegenerative disorders #Parkinson's #Phase II trial

Gene therapy proved to be safe in patients with Parkinson’s disease

Askbio’s AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no serious adverse events in a Phase Ib clinical trial. The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado,… Read More

#News #Trending News